- Home
- UWMC vs VIR Comparison
UWMC vs VIR Comparison
Compare UWMC & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- VIR
- Stock Information
- Founded
- UWMC 1986
- VIR 2016
- Country
- UWMC United States
- VIR United States
- Employees
- UWMC N/A
- VIR N/A
- Industry
- UWMC Finance: Consumer Services
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- UWMC Finance
- VIR Health Care
- Exchange
- UWMC Nasdaq
- VIR Nasdaq
- Market Cap
- UWMC 825.8M
- VIR 706.4M
- IPO Year
- UWMC N/A
- VIR 2019
- Fundamental
- Price
- UWMC $4.16
- VIR $5.65
- Analyst Decision
- UWMC Hold
- VIR Strong Buy
- Analyst Count
- UWMC 8
- VIR 8
- Target Price
- UWMC $6.18
- VIR $30.25
- AVG Volume (30 Days)
- UWMC 7.6M
- VIR 1.2M
- Earning Date
- UWMC 08-05-2025
- VIR 07-31-2025
- Dividend Yield
- UWMC 9.58%
- VIR N/A
- EPS Growth
- UWMC N/A
- VIR N/A
- EPS
- UWMC N/A
- VIR N/A
- Revenue
- UWMC $2,486,541,000.00
- VIR $20,861,000.00
- Revenue This Year
- UWMC $11.32
- VIR N/A
- Revenue Next Year
- UWMC $22.84
- VIR $0.62
- P/E Ratio
- UWMC N/A
- VIR N/A
- Revenue Growth
- UWMC 10.39
- VIR N/A
- 52 Week Low
- UWMC $3.80
- VIR $4.32
- 52 Week High
- UWMC $9.74
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- UWMC 48.32
- VIR 57.21
- Support Level
- UWMC $4.03
- VIR $5.20
- Resistance Level
- UWMC $4.32
- VIR $6.23
- Average True Range (ATR)
- UWMC 0.16
- VIR 0.30
- MACD
- UWMC 0.01
- VIR 0.07
- Stochastic Oscillator
- UWMC 44.32
- VIR 56.06
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.